CDH2 and neoplasm: In 2010, two monoclonal antibodies of N-cadherin were developed that inhibit the invasiveness and proliferation of N-cadherin-expressing cancer cells in vitro and suppress tumor growth and lymph-node metastasis in vivo (200).